Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study

Bogart, Michael; Stanford, Richard H.; Reinsch, Tyler; Hüll, Michael; Buikema, Ami; Hulbert, E.

doi:10.1016/j.rmed.2018.07.009

Cited by 23 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies have shown that a history of exacerbations is predictive of the future risk of exacerbations, [3–6, 16, 17] which was observed in our study as well. We found that frequent exacerbators (≥2 exacerbations) continued to be exacerbators (≥1 exacerbations) in the subsequent follow-up.…”

Section: Discussionsupporting

confidence: 89%

“…A previous study in COPD population without excluding patients with concurrent asthma from the UK had reported 20% of patients with eosinophil counts, of which approximately 65% had eosinophil count ≥150 cells/μL [3]. In another study, 20% of patients had eosinophil count ≥300 cells/μL and 11% had ≥400 cells/μL [6].…”

Section: Discussionmentioning

confidence: 99%

“…In these studies patients with previous asthma were allowed [1] or the proportion of patients with frequent exacerbations and high eosinophil count constituted about 5 to 10% of the total study population [1, 2]. Retrospective studies in clinical practice have shown that a substantial proportion of patients receive triple therapy [3–5], suggesting a large number of patients with COPD receive ICS irrespective of their exacerbation status.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

et al. 2019

View full text Add to dashboard Cite

Background Blood eosinophil counts and history of exacerbations have been proposed as predictors of patients with chronic obstructive pulmonary disease (COPD) who may benefit from triple therapy (inhaled corticosteroid, long-acting β 2 -agonist and long-acting muscarinic antagonist). Methods In a retrospective cohort analysis we examined the profiles of COPD patients from the UK Clinical Practice Research Datalink (CPRD) and US Optum Clinformatics™ Data Mart (Optum) databases with reference to exacerbation frequency and blood eosinophil distribution. Results Of the 31,437 (CPRD) and 383,825 (Optum) patients with COPD, 15,364 (CPRD) and 139,465 (Optum) met the eligibility criteria and were included. Among patients with ≥2 exacerbations and available eosinophil counts in the baseline period (CPRD, n = 3089 and Optum, n = 13414), 17.0 and 13.3% respectively had eosinophil counts ≥400 cells/μL. Patients with ≥2 exacerbations or eosinophil count ≥400 cells/μL during first year, exacerbated at least once (CPRD, 82.8% vs Optum, 80.6%) or continued to have eosinophil count ≥300 cells/μL (76.8% vs 76.5%), respectively in the follow-up year. In both years, a higher variability in the number of exacerbations and eosinophil count was observed in patients with one exacerbation and eosinophil counts between 300 and 400 cells/μL; patients with eosinophil count < 150 cells/μL had the lowest variability. Approximately 10% patients had both ≥2 exacerbations and eosinophil count ≥300 cells/μL across the databases. Conclusion A high variability in blood eosinophil counts over two consecutive years was observed in UK and US patients with COPD and should be considered while making treatment decisions. A small proportion of COPD patients had frequent exacerbations and eosinophil count ≥300 cells/μL. Electronic supplementary material The online version of this article (10.1186/s12931-019-1130-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, other factors such as exposure to air pollutants, may increase oxidative stress and inflammation in the lungs and contribute to the susceptibility of development of COPD. 2 COPD encompasses two serious lung disease emphysema and chronic bronchitis (CB) which results in chronic airway inflammation and progressive loss of lung function, making it difficult to breathe normally. 3 COPD is a chronic, non-communicable disease which poses a continuous burden on health care infrastructure.…”

Section: Introductionmentioning

confidence: 99%

“…Current treatment guidelines recommend the use of triple therapy with an ICS/LAMA/LABA for patients currently on bronchodilators with continued persistent symptoms and/or at risk for future exacerbations. 2,6,7 Prescription pattern monitoring studies (PPMS) are drug utilization study which is a tool that mainly focuses on prescribing and administering of drugs. They promote appropriate use of monitored drugs and reduction of abuse or misuse of monitored drugs.…”

Section: Introductionmentioning

confidence: 99%

Study of Prescribing Pattern of Drugs in Chronic Obstructive Pulmonary Disease in Tertiary Care Teaching Hospital

Kumar¹,

Madhuri²,

Wilson³

et al. 2019

IJOPP

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease, a common preventable and treatable disease has been a major public health problem in this century and is one of the leading causes of morbidity and mortality in the industrialized and the developing countries. Irrational use of drugs is a major concern in modern clinical practice; more than half of all medicines are prescribed, dispensed inappropriately. This was a prospective study with an aim to analyze the drug prescribing pattern in chronic obstructive pulmonary disease patients. Materials and Methods: The study was conducted in 163 patients of either sex admitted in the general and pulmonary medicine departments over six months from September 2017 to February 2018 at NMCH and RC, Raichur, Karnataka. Results: Out of 163 study population male patients were more (82%) and majority of the patients were from the age group of 58-68 years (45.73%). It was found that smoking was more prominent in study population (39.63%). Bronchodilators were mostly prescribed class of drugs (31.94%) in the management of COPD followed by antibiotics (25.58%). Salbutamol with budesonide combination therapy was given in majority of prescriptions. Hypertension (19.63%) was the most common co-morbidity. Generic drug prescriptions were found low (1.42% drugs). Conclusion: The study concludes that symptomatic treatment was given for COPD patients in our hospital. Combination therapy was preferred over monotherapy. Bronchodilators were the mostly prescribed class of drugs among COPD drugs. Antimicrobial therapy was given for all patients. Polypharmacy was found in all prescriptions. Diagnosis of COPD lacked spirometry.

show abstract

Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease

Mannino

et al. 2022

Pulm Ther

View full text Add to dashboard Cite

Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study

Abstract: Overall, it appears that in this patient population, ICS/LAMA/LABA as triple therapy is being initiated after use of a bronchodilator and/or after an exacerbation event, in accordance with accepted treatment recommendations.

Cited by 23 publications

References 26 publications

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

Study of Prescribing Pattern of Drugs in Chronic Obstructive Pulmonary Disease in Tertiary Care Teaching Hospital

Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About